Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma
Singal, Amit G., Agopian, Vatche G, Dawson, Laura A., El-Khoueiry, Anthony, Finn, Richard S, Halazun, Karim, Kelley, Robin Katie, Kim, Edward , Kulik, Laura, Mehta, Neil, Meyer, Jeffrey , Parikh, Neehar D. , Pillai, Anjana, Salem, Riad, Sapisochin, Gonzalo, Tabrizian, Parissa , Yopp, Adam, Yarchoan, Mark, Parikh, Neehar D , Singal, Amit G. , Agopian, Vatche G. , Dawson, Laura A. , El-Khoueiry, Anthony B. , Finn, Richard S. , Halazun, Karim J. , Heimbach, Julie K. , Kelley, Robin Kate , Kulik, Laura , Mehta, Neil , Mendiratta-Lala, Mishal , Meyer, Jeffrey, Pillai, Anjana , Salem, Riad , Sapisochín, Gonzalo , Yopp, Adam C. , Yarchoan, Mark

Mayo Clinic

Hepatology | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001834 | PMID 42565685 Get It

Background : Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Optimal treatment decisions are challenging, and existing treatment allocation frameworks may not fully reflect the evolving therapeutic landscape or contemporary clinical practices in North America. Methods : Using a modified Delphi process, a multidisciplinary panel of 20 North American experts in hepatology, medical oncology, surgery, radiology, and radiation oncology developed a consensus-based treatment framework for HCC, termed the BEACON-HCC system. The framework was informed by current evidence and expert opinion through iterative discussion and voting. In a pilot study using 29 real-world patient cases, we assessed concordance between external expert recommendations and BEACON-HCC recommendations and Barcelona Clinic Liver Cancer (BCLC) 2025 treatment recommendations. Results : The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic-locoregional combination therapies. In the pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations and 72.4% concordance with BCLC recommendations. Conclusions : BEACON-HCC is a consensus-based framework for treatment allocation that incorporates the expanding range of therapeutic options available to patients in the North American HCC population. Expert treatment decisions showed a high concordance with the BEACON-HCC system; further validation using empiric clinical data is planned through the HCC-Live Consortium.
Real-World Study of Clinical Outcomes in Patients With Spontaneous Bacterial Peritonitis Receiving Albumin
Duong, Nikki, Kim, W. Ray, Ardiles, Thomas, Lodaya, Kunal, Lilley, Jonathan, Wadhwani, Nisha, Hyatt, Hayden W., Rajkumar, Rahul, Duong, Nikki , Viayna, Elisabet , Hyatt, Hayden W. , Rajkumar, Rahul

Mayo Clinic

Journal of Clinical Gastroenterology | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mcg.0000000000002426 | PMID 42561930 Get It

Background and Goals: Spontaneous bacterial peritonitis (SBP) is a serious complication in patients with cirrhosis and ascites, with additional risks posed by multidrug-resistant organisms (MDRO). This real-world study evaluated clinical outcomes in patients with SBP and the impact of MDRO. Methods: This study identified US adults with SBP receiving guideline-recommended treatment with antibiotics and albumin from January 2012 to June 2022. Antibiotic utilization trends, health care resource utilization, and clinical outcomes [in-hospital and ICU mortality and hospital and ICU length of stay (LOS)] were assessed and stratified by MDRO status. Results: A total of 10,956 patients with 12,570 encounters were identified. Median age was 57.0 years (IQR=49.0 to 65.0), and 62.4% were male; suspected MDRO infections occurred in 15% of encounters. Third-generation cephalosporins were used in 71.6%, 49.2% had acute kidney injury, and 20.0% and 7.2% had hepatorenal syndrome and hepatic encephalopathy, respectively. Median hospital LOS was 7.2 days (IQR=4.3 to 12.9), with 17.7% in-hospital mortality. ICU care was required in 14.5% of encounters, with a median ICU LOS of 3.6 days (IQR=1.7 to 6.7) and ICU mortality of 29.7%. MDRO infections were associated with increased in-hospital mortality (OR=2.24, P <0.001) and decreased hazard of hospital discharge (ie, prolonged LOS; HR=0.43, P <0.001). Receiving albumin within 24 hours of admission was associated with a 72% higher hazard of hospital discharge (ie, shorter LOS; HR=1.72, P <0.001). Conclusion: This study highlights the clinical and resource burden of SBP, emphasizing the impact of MDRO infections and the importance of timely albumin administration concordant with clinical guidelines.
The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists
Lee, Hyunsuk , Christie, Hannah E. , Lee, Ji Seon , Kwon, Woo Il, Moon, Min Kyong , Choi, Sung Hee , Lee, Dae Ho , Lee, Seunggeun , Kho, Minjung , Man, Chiara Dalla , Cho, Nam H. , Park, Jongseok , Jo, Yeeun , Boscolo, Federica , Dalla Man, Chiara , Cho, Nam H , Choi, Jaewon , Vella, Adrian , Kwak, Soo Heon , Kim, Jong-Il , Park, Kyong Soo , Christie, Hannah E , Lee, Hyunbeom , Boscolo, Francesca S. , Lee, Jeongeun, Lee, Sangwon , Vella, Adrian

Mayo Clinic

Diabetes Care | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/dc26-0662 | PMID 42561183 Get It

OBJECTIVE Genetic variation in the glucagon-like peptide 1 receptor (GLP1R) has been implicated in type 2 diabetes (T2D) risk and treatment response. We investigated whether GLP1R R131Q, which was previously reported as a T2D-protective variant in genome-wide association studies, alters receptor signaling, β-cell function, and response to glucagon-like peptide 1 receptor agonists (GLP-1RAs). RESEARCH DESIGN AND METHODS Trajectory of β-cell function was evaluated in a 20-year community-based prospective cohort in Korea (n = 6,373), where participants underwent biennial 2-h 75-g oral glucose tolerance tests, and disposition index was used as surrogate marker. Pharmacogenetic response to GLP-1RAs was assessed in a hospital-based T2D cohort in Korea (n = 177). Hyperglycemic clamp studies (n = 17), human islet experiments (n = 21), and in vitro assays were conducted to characterize GLP1R R131Q effects on receptor signaling and islet function. RESULTS GLP1R R131Q was associated with slower decline in disposition index in individuals without T2D, with reductions from baseline of 30% in homozygous carriers, 35% in heterozygotes, and 37% in wild-type individuals. In people with T2D, each allele conferred an additional 0.53% or 5.8 mmol/mol reduction in HbA1c after 6 months of GLP-1RA treatment (P = 5.8 × 10−4). Hyperglycemic clamp and human islet experiments demonstrated allele-dependent enhancement of GLP-1RA–stimulated insulin secretion (P = 0.050 and P = 0.037, respectively). In vitro, GLP1R R131Q increased GLP-1RA–stimulated cAMP production with directional observations consistent with pathway bias. CONCLUSIONS GLP1R R131Q is a gain-of-function variant associated with preservation of β-cell function and enhanced glycemic response to GLP-1RA treatment, supporting further investigation as a candidate pharmacogenetic marker for precision diabetes care.
Beyond Doppler: Scalable AI Detection of LVOT Obstruction in HCM
Crystal, Owen , Farina, Juan M. , Scalia, Isabel G. , Ayoub, Chadi , Chollet, Laurève , Park, Hyung‐Bok , Kim, Kyung An , Arsanjani, Reza , Lester, Steven J., Crystal, Owen R , Villa Etchegoyen, Cecilia , Chollet, Laurève , Park, Hyung Bok , Kim, Kyung An , Arsanjani, Reza , Banerjee, Imon , Farina, Juan M , Scalia, Isabel G , Etchegoyen, Cecilia Villa , Lester, Steven J., Banerjee, Imon

Mayo Clinic

Circulation: Cardiovascular Imaging | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circimaging.126.019956 | PMID 42558066 Get It

BACKGROUND: Accurate assessment of left ventricular outflow tract (LVOT) gradients is critical for hypertrophic cardiomyopathy management, yet Doppler-based measurements are technically demanding and require expertise. The objective of this work was to develop a multi-view deep learning model capable of classifying LVOT obstruction (>20 mm Hg) using routine 2-dimensional echocardiographic windows without reliance on Doppler imaging. METHODS: We trained and externally validated a cross-attention-based video-to-video fusion framework that integrated EchoPrime-derived video representations from 3 standard transthoracic echocardiographic views to classify LVOT gradients. RESULTS: Training was performed on a derivation cohort (N=1833) from a tertiary care system in the United States, with model performance evaluated on an internally held-out test set (N=275) and a Korean external validation cohort (N=46). Single-view baselines showed limited discrimination (external area under the receiver operating curves, 0.47–0.70). Conversely, the domain-specific foundational model (EchoPrime) achieved superior single-view performance (area under the receiver operating curves, 0.75–0.80 internal; 0.79–0.83 external), highlighting the importance of echo-specific pretraining and temporal modeling. The proposed multi-view fusion further enhanced predictive performance, with the late fusion model reaching an area under the receiver operating curve of 0.84 on the external cohort with significant population-shift. CONCLUSIONS: These results suggest LVOT physiology is encoded in routine 2-dimensional imaging and can be leveraged for clinically relevant gradient classification without Doppler input. The proposed artificial intelligence-guided strategy demonstrates substantial cost savings compared with the screen-all approach. By integrating complementary spatial-temporal information across multiple views, our approach generalizes robustly across populations and may enable real-time decision support, extend LVOT assessment to portable or resource-limited settings, and complement Doppler-based evaluation for longitudinal hypertrophic cardiomyopathy management.
Intracranial dural arteriovenous fistulas with perimedullary venous drainage: analysis of the multinational CONDOR registry
Potgieser, Adriaan R. E., Hallak, Hana , Connor, Michelle, Yuan, Jane , Lanzino, Giuseppe, Kim, Louis J., Levitt, Michael R., Samaniego, Edgar A., Alaraj, Ali, Starke, Robert M., Abla, Adib A., Koch, Matthew, Sheehan, Jason P., Gross, Bradley A., Satomi, Junichiro, Tada, Yoshiteru , Bulters, Diederik O., Hosainey, Sayied Abdol Mohieb , Du, Rose, Lawton, Michael T., Abecassis, Isaac Josh, Amin-Hanjani, Sepideh, Nguyen, Quang, Osbun, Joshua W., Zipfel, Gregory J., Dijk, J. Marc C. van, Dijk, J. Marc C. van , van DijK, J Marc C , Moniz‐Garcia, Diogo , Lanzino, Giuseppe , Kim, Louis J. , Levitt, Michael R. , Hayakawa, M. , Samaniego, Edgar A , Alaraj, Ali , Starke, Robert M. , Abla, A, Koch, Matthew J. , Dagra, Abeer , Sheehan, Jason P. , Derdeyn, Colin P. , Gross, Bradley , Satomi, J, Bulters, Diederik , Du, Rose , Lawton, Michael T. , Ding, Dale , Amin-Hanjani, Sepideh , Nguyen, Quang, Osbun, Joshua W , Zipfel, Gregory J.

Mayo Clinic

Journal of Neurosurgery | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.3171/2026.2.jns252734 | PMID 42566799 Get It

OBJECTIVE Cognard type V dural arteriovenous fistulas (dAVFs), defined by spinal perimedullary venous drainage, represent a rare and aggressive neurovascular pathology. Comprehensive multicenter data remain scarce. The authors present the largest multicenter analysis to date, characterizing presentation, radiology, treatment, complications, and functional outcomes of Cognard type V dAVFs. METHODS The authors retrospectively analyzed patients with angiographically confirmed Cognard type V dAVFs from the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR), spanning 16 academic centers. Patient demographics, imaging features, treatment strategies, procedural complications, and modified Rankin Scale (mRS) scores were recorded. RESULTS Among 1077 patients with dAVFs, 37 (3%) had Cognard type V lesions. The mean patient age was 57 years, and 59.5% of patients were male. Most presented with nonhemorrhagic neurological deficits (68%), while 14% had hemorrhage. The most common location was the foramen magnum (32%). Embolization was the primary treatment in 67% of cases, complete obliteration was achieved in 71% of cases. Upfront microsurgery was performed in 22% of patients (obliteration rate 88%), and radiosurgery in 14% (success rate 40%). Salvage treatment further improved obliteration outcomes. Temporary complications occurred in 8% of patients (3/37): 2 with transient neurological deficits postembolization and 1 with transient hydrocephalus after surgery. Permanent complications were observed in 3% (1/37) due to treatment-related hemorrhage. At the last follow-up (mean 2.4 years), 69% (24/35) of patients maintained or improved to an mRS score ≤ 2. No deaths occurred. Functional improvement was seen in 29% (10/35), while mRS decline was in 40% of patients (14/35), all unrelated to the dAVF itself. CONCLUSIONS Cognard type V dAVFs carry a high risk of neurological morbidity. However, favorable functional outcomes are achievable with timely, multimodal intervention. Complication rates remain low, with most being transient. These data support aggressive but tailored management to prevent permanent disability in this high-risk population.
From High Cost to High Access: The Impact of Generic Abiraterone on Medicare Part D Spending in Advanced Prostate Cancer
Lee, Matthew S. , Kim, Tae-Hee , Roberson, Daniel S. , Sharma, Vidit , Wymer, Kevin , Kwon, Eugene D, Karnes, R Jeffrey, Boorjian, Stephen A. , Khanna, Abhinav

Mayo Clinic

Urology Practice | August 4, 2026 | Volume: 13 | Issue: 6 | Pages: 580-587

10.1097/upj.0000000000001066 | PMID 42550948 Get It

WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids
Jung, Dawa, Kendi, A. Tuba , Woodrum, David A. , In, Myung‐Ho , Bilgin, Gokce Belge , Johnson, Derek R. , Kim, Eun-Joo, Chung, Jin Ook , Park, Seon-Young , Curran, Geoffry L., Lowe, Val J. , Lee, Seung Baek , Kendi, A Tuba , Adamo, Daniel A. , In, Myung-Ho , Belge Bilgin, Gokce , Johnson, Derek R , Horn, Ian M, Lowe, Val J , Lee, Seung Baek , Thompson, Scott M. , Horn, Ian M. , Curran, Geoffry L.

Mayo Clinic

International Journal of Molecular Sciences | August 3, 2026 | Volume: 27 | Issue: 15 | Pages: 6899

10.3390/ijms27156899 | PMID 42589556 Get It

Long-established prostate cancer cell lines provide limited insight into how contemporary early prostate cancer evolves into drug-resistant and neuroendocrine-like refractory disease. Patient-derived three-dimensional (3D) ex vivo models may better preserve this transition. Here, we found that 8 of 10 magnetic resonance imaging-guided biopsy specimens from patients with early-stage prostate cancer generated sustained 3D tumor spheroid cultures. After 12 weeks of enzalutamide selection, only one patient-derived culture acquired a resistant phenotype with treatment-emergent neuroendocrine prostate cancer (t-NEPC)-like features, including increased chromogranin A (CgA) and synaptophysin (SYP); reduced androgen receptor (AR), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA); and conversion from compact spheroids into irregular resistant aggregates. During this transition, WD repeat and SOCS box-containing protein 1 (WSB1) increased, whereas PSMA progressively decreased. WSB1 silencing restored PSMA, AR, and PSA expression and reduced neuroendocrine-associated features. A similar WSB1 dependency was observed in enzalutamide-resistant LNCaP cells, the castration-resistant prostate cancer model 22Rv1, and the neuroendocrine/small-cell prostate cancer model NCI-H660. Mechanistically, WSB1 functioned as a SOCS box-dependent E3 ubiquitin ligase adaptor that promoted PSMA ubiquitination and degradation. SOCS box deletion or T380A mutation impaired this process, while Aurora kinase A (AURKA) inhibition reduced WSB1-dependent PSMA ubiquitination. WSB1 depletion, AURKA inhibition with alisertib, and combined AURKA inhibition with EZH2 suppression reduced resistant aggregate growth and increased apoptosis-associated markers in patient-derived enzalutamide-resistant neuroendocrine-like spheroids and related models. These findings nominate the AURKA–WSB1–PSMA axis as a therapeutic vulnerability in refractory prostate cancer.
Multilevel impairment of mitochondrial respiration in inclusion body myositis
Iaali, Hazem , Folch, N., Dasari, Surendra, Preston, Graeme, Nguyen, Thi Kim Oanh , Springer, Wolfdieter , Kozicz, Tamás , Hasadsri, Linda , Trushina, Eugenia, Shammas, Ibrahim , Vidal Folch, Noemi, Springer, Wolfdieter , Kozicz, Tamas , Hasadsri, Linda , Naddaf, Elie , Watzlawik, Jens O. , Vidal‐Folch, Noemi, Dasari, Surendra, Preston, Graeme , Trushina, Eugenia , Lanza, Ian R. , Naddaf, Elie

Mayo Clinic

Brain | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag269 | PMID 42542327 Get It

Abstract Oxidative phosphorylation (OXPHOS) is a central function and a key indicator of mitochondrial fitness, yet studies in human tissue remain limited. Inclusion body myositis (IBM) is a progressive myopathy that lies at the intersection of aging, inflammation and mitochondrial dysfunction. We aimed to perform a comprehensive profiling of mitochondrial respiration in muscle tissue from patients with IBM. A wide battery of complementary approaches from RNA level to high-resolution respirometry on permeabilized muscle fibers was employed. The relationship between mitochondrial respiration, mitochondrial content, mitochondrial DNA (mtDNA) abnormalities and mitophagy was examined, along with the correlation with various clinical parameters to determine their clinical relevance. The study included a total of 67 patients with IBM and 45 controls. On high resolution respirometry of permeabilized muscle fibers, IBM samples exhibited reduced maximal mitochondrial respiration per tissue weight in State 3 (high substrates, high ADP) and uncoupled state with decreased coupling efficiency and higher leak control ratios. When adjusting for citrate synthase reflecting mitochondrial content, male patients had decreased State 3 intrinsic respiration, whereas female patients had greater intrinsic respiration under leak states. Complex I activity was decreased mainly in female patients, in whom complex II control ratio positively correlated with disease duration and severity. IBM was further associated with decreased RNA levels of all complexes, and lower protein expression of complex I, III, IV and V, likely related to the lower mtDNA content seen in IBM samples. Regarding the production of reactive oxygen species, IBM samples exhibited lower maximal H2O2 emission, accompanied by a higher total antioxidant capacity that positively correlated with disease duration in female patients. Lastly, correlation analyses suggested that impaired mitochondrial respiration, altered mitophagy, and reduced mtDNA content are interconnected in IBM and maybe of clinical significance. IBM is characterized by multifaceted, clinically relevant impairments in mitochondrial respiration. Future studies should further explore underlying pathomechanisms and the variation of mitochondrial respiration by disease stage.
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R, Jones, Richard J., Singh, Anurag K, Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J., Üstün, Celalettin , Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias, Onozawa, Masahiro , Thomson, Kirsty , Chen, Caroline , Hasabou, Nahla, Rosales, Matt, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Mendizabal, Adam , Horowitz, Mary M, Chen, Yi‐Bin , Papadopoulos, Esperanza , Perl, Alexander E , Ustun, Celalettin , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Muffly, Lori , Kim, Hee-Je , Najima, Yuho , Onozawa, Masahiro , Hill, Jason , Devine, Steven , Chen, Yi-Bin , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Wingard, John R. , Soiffer, Robert J. , Ueda, Masumi , Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Stelljes, Matthias , Hill, Jason E. , Devine, Steven M. , Horowitz, Mary M.

Mayo Clinic

Blood Advances | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020327 | PMID 42532509 Get It

BMT CTN 1506 ("MORPHO") was a phase 3 study of post-hematopoietic cell transplantation (HCT) maintenance with gilteritinib versus placebo for patients with FLT3-ITD-mutated acute myeloid leukemia (AML) in first remission. Subgroup analysis indicated a significant benefit of post-HCT gilteritinib for participants in North America, but no benefit for those in Europe or Asia. We conducted a post-hoc analysis of the data focusing on days from AML diagnosis to HCT, pre-HCT FLT3 inhibitor use, and FLT3-ITD measurable residual disease (MRD). Participants transplanted &lt; 120 days from AML diagnosis and/or those treated with FLT3 inhibition pre-HCT were more likely to have improved survival from post-HCT gilteritinib. Pre-HCT MRD levels were higher (P = 0.001) in participants transplanted within 120 days from diagnosis and in those treated with a FLT3 inhibitor pre-HCT and transplanted within 120 days (P = 0.008). Pre-HCT MRD was dependent on both FLT3 inhibitor use and time to HCT, as participants treated with successive courses of chemotherapy + FLT3 inhibition had successively lower MRD by the time of HCT. Time from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use both appeared to impact MRD levels immediately prior to HCT, and geographic differences in these two practice patterns likely accounted for the observed regional differences in benefit from post-HCT gilteritinib. Increasing the number of courses of treatment pre-HCT may lower MRD sufficiently to eliminate the need for post-HCT inhibition, but with a presumed risk of some patients experiencing early progression. This trial was registered at www.clinicaltrials.gov as #NCT02997202.